This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > About EXJADE > Efficacy
Print

In this section:

EU SmPC

Once-daily EXJADE Provides Total Body Iron Chelation Across Anemias

EXJADE removes iron from the heart and the liver and demonstrates efficacy across clinical parameters.

The once-daily chelation therapy has a wealth of experience in more than 90,000 patients.1,2,3,4

Learn more about how EXJADE reduces toxic iron in patients with:

β-thalassemia Myelodysplastic syndrome Sickle cell disease Aplastic and other anemias

IRON TOXICITY ACROSS UNDERLYING ANEMIAS

Iron toxicity increases
morbidity and mortality
across a range of
patients.

Learn more

EXJADE reduces serum ferritin across anemias1

Click on the serum ferritin arrows to see reductions in liver iron concentration in the same patient type.


Serum Ferritin Levels Across Anemias

References

  1. Data on file. Novartis Pharma AG, Basel, Switzerland.
  2. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Lee CL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364-2371.
  3. Pennell DJ, Porter JB, Cappellini MD, Lee CL, El-Beshlawy A, Aydinok Y, et al. Efficacy and safety of deferasirox (EXJADE®) in β-thalassemia patients with myocardial siderosis: 2-year results from the EPIC cardiac sub-study. Poster presented at: 51st annual American Society of Hematology Meeting; December 5-8, 2009; New Orleans, LA.
  4. Greenberg PL, Koller CA, Cabantchik ZI, et al. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res. 2010;34(12):1560-1565.
  5. Greenberg PL, Koller CA, Glynos T, Paley C, Schiffer CA. Change in liver iron concentration, serum ferritin and labile plasma iron over 1 year of deferasirox (EXJADE®) therapy in a cohort of patients with MDS. Poster presented at 10th International Symposium on Myelodysplastic Syndromes. [P104] Leuk Res. 2009;33 (suppl 1):S120.
  6. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508.
TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed